You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
HETROM-2.5, n = 168
|
HETROM-5, n = 171
|
Placebo, n = 85
|
|---|
|
Age, median (range), years
|
38 (19–70)
|
41 (18–74)
|
42 (18–71)
|
|
Age, n (%)
|
|
18–65 years
|
162 (96.4)
|
163 (95.3)
|
82 (96.5)
|
|
> 65 years
|
6 (3.6)
|
8 (4.7)
|
3 (3.5)
|
|
Height, median (range), cm
|
162.5 (147.0–182.0)
|
161.0 (147.0–182.0)
|
162.0 (150.0–185.5)
|
|
Weight, median (range), kg
|
61.0 (39.0–115.0)
|
62.5 (43.5–110.0)
|
63.0 (44.5–88.0)
|
|
BMI, median (range), kg/m2
|
23.4 (16.9–37.6)
|
24.4 (17.3–35.9)
|
23.6 (18.0–30.5)
|
|
Female, n (%)
|
122 (72.6)
|
119 (69.6)
|
60 (70.6)
|
|
Time since first ITP diagnosis, n (%)
|
|
0.5–1 year
|
32 (19.0)
|
35 (20.5)
|
13 (15.3)
|
|
1–3 years
|
53 (31.5)
|
56 (32.7)
|
19 (22.4)
|
|
3–5 years
|
31 (18.5)
|
16 (9.4)
|
14 (16.5)
|
|
≥ 5 years
|
52 (31.0)
|
64 (37.4)
|
39 (45.9)
|
|
Prior splenectomy, n (%)
|
14 (8.3)
|
15 (8.8)
|
4 (4.7)
|
|
Bleeding (WHO bleeding scale grade 1–4), n (%)
|
108 (64.3)
|
93 (54.4)
|
52 (61.2)
|
|
Concomitant ITP medication at baseline, n (%)
|
168 (100.0)
|
168 (98.2)
|
83 (97.6)
|
|
Baseline platelet count, median (range), × 109/L
|
13 (1–29)
|
13 (2–29)
|
13 (1–29)
|
|
Baseline platelet count, n (%)
|
|
< 10 × 109/L
|
64 (38.1)
|
58 (33.9)
|
35 (41.2)
|
|
10–30 × 109/L
|
104 (61.9)
|
113 (66.1)
|
50 (58.8)
|
- HETROM-2.5, dosage was titrated from an initial dose of once-daily 2.5 mg hetrombopag; HETROM-5, dosage was titrated from an initial dose of once-daily 5 mg hetrombopag; BMI, body mass index; ITP, immune thrombocytopenia; WHO, World Health Organization
